Evgeniya S. Lylova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evgeniya S. Lylova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Kirill Igorevich Kirsanov
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 115093 Moscow, Russia
20 shared publications - Ekaterina M. Zhidkova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
17 shared publications - Marianna G. Yakubovskaya
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 115093 Moscow, Russia
12 shared publications - Alena V. Savinkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 24 Kashirskoe Shosse, 115522 Moscow, Russia
9 shared publications - Ekaterina Andreevna Lesovaya
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), Moscow 115093, Russia
8 shared publications - Anna Klopot
Department of Dermatology, Northwestern University, Chicago, Illinois, USA
7 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 14
Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.
- 23 February 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 14
Open AccessEpigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.
- Open Access
- 6 October 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (3) , 116-131
Molecular effects of the pesticides carbaryl, chlorpyrifos, mancozeb, thiram, and pendimethalin in conditionally normal cells in vitro: genotoxicity, clonogenicity and effects on the expression of genes associated with carcinogenesis
Introduction. Cancer remains a major cause of mortality worldwide, with adverse environmental factors such as pesticides contributing significantly to its development. Despite the widespread use of various pesticides, the molecular mechanisms underlying their actions and carcinogenic potential have been studied for only a limited number of models, especially in normal human cells.Aim. To study the molecular effects of pesticides carbaryl, chlorpyrifos, mancozeb, thiram, and pendimethalin in nonmalignant HaCaT and MCF10A cells.Materials and methods. Non-toxic concentrations of pesticides were determined using the MTT assay. Genotoxicity was analyzed by the comet assay. Proliferative potential was assessed by clonogenic assay. Changes in the expression of genes associated with carcinogenesis were evaluated by real-time polymerase chain reaction.Results. Carbaryl caused DNA damage in MCF10A cells, promoted proliferation in both cell lines during clonogenic assay, as well as caused activation of biotransformation genes (AHR, GSTA4) in MCF10A cells, repression (CYP1B1, GSTA4) genes in HaCaT cells and lowered expression of inflammation genes (IL1a, IL1b, PTGES, IFNGR1). Chlorpyrifos did not have genotoxic effect and did not affect clonogenicity but caused induction of biotransformation (CYP1A1, CYP1B1), inflammation (IL1b, PTGES) genes, and genes BCL2 and DNMTs. Mancozeb and thiram did not show genotoxicity in HaCaT and MCF10A cells but activated individual repair genes (ATR/ATM). Thiram stimulated HaCaT cell proliferation in clonogenic assay, and mancozeb activated expression of proliferation regulation genes (CCND2, CCNE1, Ki-67) but did not affect colony growth; both fungicides decreased expression of inflammation genes (COX2, IL1a, IL1b). Pendimethalin caused DNA damage and activation of repair genes (ATR, GADD45a, PCNA) in both cell lines, as well as decreased expression of GLUT3 in HaCaT cells and induced expression of CYP1A1 in HaCaT cells and CYP1B1 in MCF10A cells.Conclusion. In this study, we performed a comprehensive assessment of the effects of pesticides on normal human cells. Our results indicate that pendimethalin, chlorpyrifos, and carbaryl exert the most procarcinogenic effect.
- 6 October 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (3) , 116-131
Open AccessMolecular effects of the pesticides carbaryl, chlorpyrifos, mancozeb, thiram, and pendimethalin in conditionally normal cells in vitro: genotoxicity, clonogenicity and effects on the expression of genes associated with carcinogenesis
Introduction. Cancer remains a major cause of mortality worldwide, with adverse environmental factors such as pesticides contributing significantly to its development. Despite the widespread use of various pesticides, the molecular mechanisms underlying their actions and carcinogenic potential have been studied for only a limited number of models, especially in normal human cells.Aim. To study the molecular effects of pesticides carbaryl, chlorpyrifos, mancozeb, thiram, and pendimethalin in nonmalignant HaCaT and MCF10A cells.Materials and methods. Non-toxic concentrations of pesticides were determined using the MTT assay. Genotoxicity was analyzed by the comet assay. Proliferative potential was assessed by clonogenic assay. Changes in the expression of genes associated with carcinogenesis were evaluated by real-time polymerase chain reaction.Results. Carbaryl caused DNA damage in MCF10A cells, promoted proliferation in both cell lines during clonogenic assay, as well as caused activation of biotransformation genes (AHR, GSTA4) in MCF10A cells, repression (CYP1B1, GSTA4) genes in HaCaT cells and lowered expression of inflammation genes (IL1a, IL1b, PTGES, IFNGR1). Chlorpyrifos did not have genotoxic effect and did not affect clonogenicity but caused induction of biotransformation (CYP1A1, CYP1B1), inflammation (IL1b, PTGES) genes, and genes BCL2 and DNMTs. Mancozeb and thiram did not show genotoxicity in HaCaT and MCF10A cells but activated individual repair genes (ATR/ATM). Thiram stimulated HaCaT cell proliferation in clonogenic assay, and mancozeb activated expression of proliferation regulation genes (CCND2, CCNE1, Ki-67) but did not affect colony growth; both fungicides decreased expression of inflammation genes (COX2, IL1a, IL1b). Pendimethalin caused DNA damage and activation of repair genes (ATR, GADD45a, PCNA) in both cell lines, as well as decreased expression of GLUT3 in HaCaT cells and induced expression of CYP1A1 in HaCaT cells and CYP1B1 in MCF10A cells.Conclusion. In this study, we performed a comprehensive assessment of the effects of pesticides on normal human cells. Our results indicate that pendimethalin, chlorpyrifos, and carbaryl exert the most procarcinogenic effect.
- Open Access
- 9 December 2024
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 11 (4) , 66-79
Molecular mechanisms of action of curaxin CBL0137 on breast cancer cells in vitro
Introduction. Breast cancer (BC) represents a group of malignant neoplasms with various molecular profiles, which are characterized by aberrations in the mechanisms of epigenetic transcription regulation. One of these disruptions associated with a worse prognosis is the overexpression of the BET protein family, responsible for the interaction of transcription factors with histone-rich acetylated regions. Previously, for the multitargeted epigenetically active agent curaxin CBL0137 (CBL), we have shown the ability to inhibit the expression of BRD2, BRD3, BRD4 proteins in HeLa TI cells and BRD3, BRD4 proteins in BC cells.Aim. To analyze the molecular mechanisms of CBL0137 action on BC cells in vitro, including: 1) assessment of cytotoxicity, 2) analysis of the effect on the cell cycle, 3) assessment of the ability to trigger apoptosis, 4) cause DNA damage, and 5) analyze the effect on the expression of genes involved in proliferation, apoptosis and repair processes.Materials and methods. The cytotoxicity of CBL on BC cells (MCF7, MDA-MB-231, SKBR3) was assessed using the MTT assay. The effect of the agent on the cell cycle and activation of apoptosis was analyzed by flow cytometry. Analysis of DNA damage under the action of CBL was performed using the comet assay. Changes in the expression of genes associated with proliferation, repair and apoptosis were evaluated using real-time polymerase chain reaction.Results. The half maximal inhibitory concentration (IC50) on BC cells under the action of CBL0137 were 1 μM at 72-hour exposure, 14–25 μM at 24-hour. Curaxin CBL (0.5 and 1 μM) caused G2/M cell cycle arrest, and also triggered apoptosis in all cell lines. Under the action of 1 μM CBL, an increase in the degree of DNA damage in MCF7 and SKBR3 cells was recorded, and under the action of both concentrations in MDA-MB-231 cells. The gene expression profile involved in proliferation also corresponded to the arrest in the G2/M phase of the cell cycle. Also, under the action of CBL, the activation of p53-dependent repair genes occurred. An increase in the expression of pro-apoptotic and a decrease in anti-apoptotic genes was shown.Conclusion. Curaxin CBL0137 showed differential effects on molecular processes in BC cells. We have identified a cytostatic effect of the compound, confirmed at various molecular levels. The data obtained indicate the ability of CBL0137 to inhibit tumor processes in BC cells, which makes it a potentially interesting agent for combination therapy.
- 9 December 2024
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 11 (4) , 66-79
Open AccessMolecular mechanisms of action of curaxin CBL0137 on breast cancer cells in vitro
Introduction. Breast cancer (BC) represents a group of malignant neoplasms with various molecular profiles, which are characterized by aberrations in the mechanisms of epigenetic transcription regulation. One of these disruptions associated with a worse prognosis is the overexpression of the BET protein family, responsible for the interaction of transcription factors with histone-rich acetylated regions. Previously, for the multitargeted epigenetically active agent curaxin CBL0137 (CBL), we have shown the ability to inhibit the expression of BRD2, BRD3, BRD4 proteins in HeLa TI cells and BRD3, BRD4 proteins in BC cells.Aim. To analyze the molecular mechanisms of CBL0137 action on BC cells in vitro, including: 1) assessment of cytotoxicity, 2) analysis of the effect on the cell cycle, 3) assessment of the ability to trigger apoptosis, 4) cause DNA damage, and 5) analyze the effect on the expression of genes involved in proliferation, apoptosis and repair processes.Materials and methods. The cytotoxicity of CBL on BC cells (MCF7, MDA-MB-231, SKBR3) was assessed using the MTT assay. The effect of the agent on the cell cycle and activation of apoptosis was analyzed by flow cytometry. Analysis of DNA damage under the action of CBL was performed using the comet assay. Changes in the expression of genes associated with proliferation, repair and apoptosis were evaluated using real-time polymerase chain reaction.Results. The half maximal inhibitory concentration (IC50) on BC cells under the action of CBL0137 were 1 μM at 72-hour exposure, 14–25 μM at 24-hour. Curaxin CBL (0.5 and 1 μM) caused G2/M cell cycle arrest, and also triggered apoptosis in all cell lines. Under the action of 1 μM CBL, an increase in the degree of DNA damage in MCF7 and SKBR3 cells was recorded, and under the action of both concentrations in MDA-MB-231 cells. The gene expression profile involved in proliferation also corresponded to the arrest in the G2/M phase of the cell cycle. Also, under the action of CBL, the activation of p53-dependent repair genes occurred. An increase in the expression of pro-apoptotic and a decrease in anti-apoptotic genes was shown.Conclusion. Curaxin CBL0137 showed differential effects on molecular processes in BC cells. We have identified a cytostatic effect of the compound, confirmed at various molecular levels. The data obtained indicate the ability of CBL0137 to inhibit tumor processes in BC cells, which makes it a potentially interesting agent for combination therapy.
- Open Access
- 12 April 2024
- Published by MDPI AG in Proceedings
- Vol. 103 (1) , 73
Anticancer Effects of the Potential BET Inhibitor CBL0137 on Breast Cancer Cells
Breast cancer (BC) is a complex disease driven by a combination of genetic mutations and epigenetic modifications. In particular, the overexpression of BET family proteins (BETs) has emerged as a key epigenetic aberration contributing to BC pathogenesis. CBL0137 (CBL), a small-molecule compound, has shown promise as an inhibitor of BETs in HeLa TI cells. In this study, we aimed to assess the anticancer effects of CBL in vitro and evaluate its impact on the expression of BETs in BC cells. Cells of three subtypes of BC (MCF7, MDA-MB-231, SKBR3) were used in this study. Cytotoxic effects were analyzed using the MTT assay. Effects on cell cycle and apoptosis were assessed using FACS with PI and FITC-Annexin staining. The level of BETs (BRD2, BRD3, BRD4) was determined by Western blotting. CBL demonstrated a significant reduction in BС cell viability with an IC50 value of approximately 1 μM for all cell lines after 72h of exposure and 20 μM after 24h. CBL treatment resulted in an increase in cells in the G2/M phase in MCF7 and SKBR3 cells after 24h and 72h of action, as well as in MDA-MB-231 cells after 24h. In MCF7 cells, the influence of CBL led to apoptotic changes characterized by a slight elevation in the early apoptotic population. Treatment of MDA-MB-231 cells with CBL resulted in a decrease in the expression of BRD2, BRD3, and BRD4 proteins, while treatment of MCF7 cells led to a reduction in BRD3 and BRD4 protein levels. No significant changes in the amount of BET proteins were observed in SKBR3 cells. In conclusion, the presented data offer valuable insights into the mechanisms of action of CBL, providing a basis for further investigation into its therapeutic potential in BC treatment. This research was funded by the RSF (no. 21-75-10163).
- 12 April 2024
- Published by MDPI AG in Proceedings
- Vol. 103 (1) , 73
Open AccessAnticancer Effects of the Potential BET Inhibitor CBL0137 on Breast Cancer Cells
Breast cancer (BC) is a complex disease driven by a combination of genetic mutations and epigenetic modifications. In particular, the overexpression of BET family proteins (BETs) has emerged as a key epigenetic aberration contributing to BC pathogenesis. CBL0137 (CBL), a small-molecule compound, has shown promise as an inhibitor of BETs in HeLa TI cells. In this study, we aimed to assess the anticancer effects of CBL in vitro and evaluate its impact on the expression of BETs in BC cells. Cells of three subtypes of BC (MCF7, MDA-MB-231, SKBR3) were used in this study. Cytotoxic effects were analyzed using the MTT assay. Effects on cell cycle and apoptosis were assessed using FACS with PI and FITC-Annexin staining. The level of BETs (BRD2, BRD3, BRD4) was determined by Western blotting. CBL demonstrated a significant reduction in BС cell viability with an IC50 value of approximately 1 μM for all cell lines after 72h of exposure and 20 μM after 24h. CBL treatment resulted in an increase in cells in the G2/M phase in MCF7 and SKBR3 cells after 24h and 72h of action, as well as in MDA-MB-231 cells after 24h. In MCF7 cells, the influence of CBL led to apoptotic changes characterized by a slight elevation in the early apoptotic population. Treatment of MDA-MB-231 cells with CBL resulted in a decrease in the expression of BRD2, BRD3, and BRD4 proteins, while treatment of MCF7 cells led to a reduction in BRD3 and BRD4 protein levels. No significant changes in the amount of BET proteins were observed in SKBR3 cells. In conclusion, the presented data offer valuable insights into the mechanisms of action of CBL, providing a basis for further investigation into its therapeutic potential in BC treatment. This research was funded by the RSF (no. 21-75-10163).
- Open Access
- 17 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12874
Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
The development of malignant tumors is caused by a complex combination of genetic mutations and epigenetic alterations, the latter of which are induced by either external environmental factors or signaling disruption following genetic mutations. Some types of cancer demonstrate a significant increase in epigenetic enzymes, and targeting these epigenetic alterations represents a compelling strategy to reverse cell transcriptome to the normal state, improving chemotherapy response. Curaxin CBL0137 is a new potent anticancer drug that has been shown to activate epigenetically silenced genes. However, its detailed effects on the enzymes of the epigenetic system of transcription regulation have not been studied. Here, we report that CBL0137 inhibits the expression of DNA methyltransferase DNMT3a in HeLa TI cells, both at the level of mRNA and protein, and it decreases the level of integral DNA methylation in Ca Ski cells. For the first time, it is shown that CBL0137 decreases the level of BET family proteins, BRD2, BRD3, and BRD4, the key participants in transcription elongation, followed by the corresponding gene expression enhancement. Furthermore, we demonstrate that CBL0137 does not affect the mechanisms of histone acetylation and methylation. The ability of CBL0137 to suppress DNMT3A and BET family proteins should be taken into consideration when combined chemotherapy is applied. Our data demonstrate the potential of CBL0137 to be used in the therapy of tumors with corresponding aberrant epigenetic profiles.
- 17 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12874
Open AccessInsights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
The development of malignant tumors is caused by a complex combination of genetic mutations and epigenetic alterations, the latter of which are induced by either external environmental factors or signaling disruption following genetic mutations. Some types of cancer demonstrate a significant increase in epigenetic enzymes, and targeting these epigenetic alterations represents a compelling strategy to reverse cell transcriptome to the normal state, improving chemotherapy response. Curaxin CBL0137 is a new potent anticancer drug that has been shown to activate epigenetically silenced genes. However, its detailed effects on the enzymes of the epigenetic system of transcription regulation have not been studied. Here, we report that CBL0137 inhibits the expression of DNA methyltransferase DNMT3a in HeLa TI cells, both at the level of mRNA and protein, and it decreases the level of integral DNA methylation in Ca Ski cells. For the first time, it is shown that CBL0137 decreases the level of BET family proteins, BRD2, BRD3, and BRD4, the key participants in transcription elongation, followed by the corresponding gene expression enhancement. Furthermore, we demonstrate that CBL0137 does not affect the mechanisms of histone acetylation and methylation. The ability of CBL0137 to suppress DNMT3A and BET family proteins should be taken into consideration when combined chemotherapy is applied. Our data demonstrate the potential of CBL0137 to be used in the therapy of tumors with corresponding aberrant epigenetic profiles.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-3 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Tables 1-3. Suppl. Table 1 contains the list of REDD1 inhibitors identified by computational screen and selected for study. Suppl. Table 2 contains primer sets for Q-PCR analysis. Suppl. Table 3 contains IC50 values of WM, LY294002 and AZD8055 after 24 h of incubation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Tables 1-3. Suppl. Table 1 contains the list of REDD1 inhibitors identified by computational screen and selected for study. Suppl. Table 2 contains primer sets for Q-PCR analysis. Suppl. Table 3 contains IC50 values of WM, LY294002 and AZD8055 after 24 h of incubation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Glucocorticoids are widely used for therapy of hematologic malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays central role in steroid atrophy. Here, we tested whether REDD1 suppression makes glucocorticoid-based therapy of blood cancer safer. Unexpectedly, approximately 50% of top putative REDD1 inhibitors selected by bioinformatics screening of Library of Integrated Network-Based Cellular Signatures database (LINCS) were PI3K/Akt/mTOR inhibitors. We selected Wortmannin, LY294002, and AZD8055 for our studies and showed that they blocked basal and glucocorticoid-induced REDD1 expression. Moreover, all PI3K/mTOR/Akt inhibitors modified glucocorticoid receptor function shifting it toward therapeutically important transrepression. PI3K/Akt/mTOR inhibitors enhanced anti-lymphoma effects of Dexamethasone in vitro and in vivo, in lymphoma xenograft model. The therapeutic effects of PI3K inhibitor+Dexamethasone combinations ranged from cooperative to synergistic, especially in case of LY294002 and Rapamycin, used as a previously characterized reference REDD1 inhibitor. We found that coadministration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis. Together, our results provide foundation for further development of safer and more effective glucocorticoid-based combination therapy of hematologic malignancies using PI3K/Akt/mTOR inhibitors.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Glucocorticoids are widely used for therapy of hematologic malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays central role in steroid atrophy. Here, we tested whether REDD1 suppression makes glucocorticoid-based therapy of blood cancer safer. Unexpectedly, approximately 50% of top putative REDD1 inhibitors selected by bioinformatics screening of Library of Integrated Network-Based Cellular Signatures database (LINCS) were PI3K/Akt/mTOR inhibitors. We selected Wortmannin, LY294002, and AZD8055 for our studies and showed that they blocked basal and glucocorticoid-induced REDD1 expression. Moreover, all PI3K/mTOR/Akt inhibitors modified glucocorticoid receptor function shifting it toward therapeutically important transrepression. PI3K/Akt/mTOR inhibitors enhanced anti-lymphoma effects of Dexamethasone in vitro and in vivo, in lymphoma xenograft model. The therapeutic effects of PI3K inhibitor+Dexamethasone combinations ranged from cooperative to synergistic, especially in case of LY294002 and Rapamycin, used as a previously characterized reference REDD1 inhibitor. We found that coadministration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis. Together, our results provide foundation for further development of safer and more effective glucocorticoid-based combination therapy of hematologic malignancies using PI3K/Akt/mTOR inhibitors.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-9 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Figures 1-9. Suppl. Fig. 1 contains quantification of Western blots. Suppl. Fig. 2 demonstrates the effect of PI3K/mTOR/Akt inhibitors on regulation of endogenous genes by Dex in CEM and Granta cells. Suppl. Fig. 3 shows cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM and Granta cells. Suppl. Fig. 4 demonstrates cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM cells, Granta cells and normal human monocytes. Suppl. Fig. 5 shows anti-lymphoma effect of Rapamycin and Dex in CEM and Granta cells. Suppl. Fig. 6 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in xenograft study. Suppl. Fig. 7 shows anti-tumor effect of Dex, Rapa, LY294002 on Granta xenografts. Suppl. Fig. 8 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in Dexamethasone-induced osteoporosis study. Suppl. Fig. 9 shows the data on Q-PCR analysis of Col1a1 and Col2a1 mRNA expression in bone tissue.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-9 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Figures 1-9. Suppl. Fig. 1 contains quantification of Western blots. Suppl. Fig. 2 demonstrates the effect of PI3K/mTOR/Akt inhibitors on regulation of endogenous genes by Dex in CEM and Granta cells. Suppl. Fig. 3 shows cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM and Granta cells. Suppl. Fig. 4 demonstrates cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM cells, Granta cells and normal human monocytes. Suppl. Fig. 5 shows anti-lymphoma effect of Rapamycin and Dex in CEM and Granta cells. Suppl. Fig. 6 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in xenograft study. Suppl. Fig. 7 shows anti-tumor effect of Dex, Rapa, LY294002 on Granta xenografts. Suppl. Fig. 8 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in Dexamethasone-induced osteoporosis study. Suppl. Fig. 9 shows the data on Q-PCR analysis of Col1a1 and Col2a1 mRNA expression in bone tissue.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-3 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Tables 1-3. Suppl. Table 1 contains the list of REDD1 inhibitors identified by computational screen and selected for study. Suppl. Table 2 contains primer sets for Q-PCR analysis. Suppl. Table 3 contains IC50 values of WM, LY294002 and AZD8055 after 24 h of incubation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Supplementary Tables 1-3. Suppl. Table 1 contains the list of REDD1 inhibitors identified by computational screen and selected for study. Suppl. Table 2 contains primer sets for Q-PCR analysis. Suppl. Table 3 contains IC50 values of WM, LY294002 and AZD8055 after 24 h of incubation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Glucocorticoids are widely used for therapy of hematologic malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays central role in steroid atrophy. Here, we tested whether REDD1 suppression makes glucocorticoid-based therapy of blood cancer safer. Unexpectedly, approximately 50% of top putative REDD1 inhibitors selected by bioinformatics screening of Library of Integrated Network-Based Cellular Signatures database (LINCS) were PI3K/Akt/mTOR inhibitors. We selected Wortmannin, LY294002, and AZD8055 for our studies and showed that they blocked basal and glucocorticoid-induced REDD1 expression. Moreover, all PI3K/mTOR/Akt inhibitors modified glucocorticoid receptor function shifting it toward therapeutically important transrepression. PI3K/Akt/mTOR inhibitors enhanced anti-lymphoma effects of Dexamethasone in vitro and in vivo, in lymphoma xenograft model. The therapeutic effects of PI3K inhibitor+Dexamethasone combinations ranged from cooperative to synergistic, especially in case of LY294002 and Rapamycin, used as a previously characterized reference REDD1 inhibitor. We found that coadministration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis. Together, our results provide foundation for further development of safer and more effective glucocorticoid-based combination therapy of hematologic malignancies using PI3K/Akt/mTOR inhibitors.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Glucocorticoids are widely used for therapy of hematologic malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays central role in steroid atrophy. Here, we tested whether REDD1 suppression makes glucocorticoid-based therapy of blood cancer safer. Unexpectedly, approximately 50% of top putative REDD1 inhibitors selected by bioinformatics screening of Library of Integrated Network-Based Cellular Signatures database (LINCS) were PI3K/Akt/mTOR inhibitors. We selected Wortmannin, LY294002, and AZD8055 for our studies and showed that they blocked basal and glucocorticoid-induced REDD1 expression. Moreover, all PI3K/mTOR/Akt inhibitors modified glucocorticoid receptor function shifting it toward therapeutically important transrepression. PI3K/Akt/mTOR inhibitors enhanced anti-lymphoma effects of Dexamethasone in vitro and in vivo, in lymphoma xenograft model. The therapeutic effects of PI3K inhibitor+Dexamethasone combinations ranged from cooperative to synergistic, especially in case of LY294002 and Rapamycin, used as a previously characterized reference REDD1 inhibitor. We found that coadministration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis. Together, our results provide foundation for further development of safer and more effective glucocorticoid-based combination therapy of hematologic malignancies using PI3K/Akt/mTOR inhibitors.